Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab in EGFR-amplified Advanced Solid Tumors
NCT06022276Phase 2Unknown
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in lung cancer, esophageal cancer, gastric cancer (GC), pancreatic cancer (PC), colorectal cancer (CRC), sponsored by The Second Hospital of Tianjin Medical University. Status: unknown.
02
Drugs
nimotuzumab
03
Conditions
lung canceresophageal cancergastric cancer (GC)pancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06022276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022276.